Welcome to our dedicated page for Avidity Biosciences SEC filings (Ticker: RNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Avidity Biosciences’ journey from lab bench to potential FDA approval means wading through dense disclosures on its Antibody Oligonucleotide Conjugate platform, clinical trial costs, and collaboration milestones. Those details hide in 200-page 10-Ks and rapid-fire 8-Ks—documents few investors have time to dissect.
Stock Titan eliminates that bottleneck. Our AI turns every Avidity Biosciences quarterly earnings report 10-Q filing, annual report 10-K simplified, and Avidity Biosciences 8-K material events explained into plain-English highlights within minutes of hitting EDGAR. Need to monitor Avidity Biosciences insider trading Form 4 transactions? We stream Form 4 insider transactions real-time, flag executive stock sales, and cross-reference them with upcoming data releases.
- AI-powered summaries clarify R&D spend, cash runway, and AOC pipeline milestones.
- Real-time alerts for Avidity Biosciences executive stock transactions Form 4.
- Side-by-side trend charts for revenue from collaborations and quarterly burn.
- Keyword search—find “del-desiran Phase 2 costs” inside hundreds of pages instantly.
Whether you’re comparing dilution risk before the next capital raise or studying compensation in the Avidity Biosciences proxy statement executive compensation, our platform answers the questions investors actually ask: “How healthy is the balance sheet?”, “Which trials are fully funded?”, “What did the CEO buy last quarter?”. Stop scrolling; start understanding Avidity Biosciences SEC documents with AI.
Avidity Biosciences, Inc. (RNA) Form 4 filing: Chief Program Officer Kathleen P. Gallagher reported a single open-market sale of company common stock executed on 06/17/2025. The sale, carried out under a previously established Rule 10b5-1 trading plan (adopted 06/12/2024), involved 911 shares at a price of $30.24 per share.
Following the transaction, Gallagher’s direct holding stands at 50,392 shares. The filing was signed on 06/18/2025 and indicates that the Form 4 was filed by one reporting person only. No derivative transactions or additional equity awards were disclosed.
The relatively small share quantity and continued sizeable ownership suggest the transaction is routine in nature rather than signaling a material change in insider sentiment.
FAQ
What is the current stock price of Avidity Biosciences (RNA)?
What is the market cap of Avidity Biosciences (RNA)?
What is Avidity Biosciences' core technology?
Which diseases are the focus of Avidity's clinical programs?
How does the AOC platform differ from traditional therapies?
What are the key clinical candidates being developed by Avidity?
What role do strategic partnerships play in Avidity's business model?
How does Avidity’s approach benefit patients with rare diseases?
What distinguishes Avidity in the competitive landscape of RNA therapeutics?
Why is the company expanding into precision cardiology?
